This is a summary of the European public assessment report (EPAR) for Invega. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Invega.
For practical information about using Invega, patients should read the package leaflet or contact their doctor or pharmacist.
Invega : EPAR - Summary for the public (PDF/80.9 KB)
First published: 04/03/2009
Last updated: 19/09/2017
Invega : EPAR - Risk-management-plan summary (PDF/88.97 KB)
First published: 13/08/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Janssen-Cilag International NV
|Date of issue of marketing authorisation valid throughout the European Union||
09/04/2021 Invega - EMEA/H/C/000746 - WS/1877
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older.
Invega is indicated for the treatment of schizoaffective disorder in adults.
Janssen-Cilag International N.V. withdraws its application for an extension of indication for Invega (paliperidone)17/12/2008